Thrixen
Singapore, Singapore· Est.
Thrixen builds rapid, affordable point‑of‑care diagnostics using engineered protein binders and a unique assay platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Thrixen builds rapid, affordable point‑of‑care diagnostics using engineered protein binders and a unique assay platform.
Infectious Diseases
Technology Platform
Engineered protein binders integrated into a versatile assay format that enables rapid, low‑cost biomarker detection on paper‑based and other inexpensive substrates.
Opportunities
Rapid growth of point‑of‑care testing, especially in emerging markets and for pandemic preparedness, offers sizable revenue potential.
Risk Factors
Regulatory approval timelines, competition from established diagnostics firms, and the need for sustained capital to scale manufacturing pose significant challenges.
Competitive Landscape
Thrixen competes with traditional antibody‑based POCT providers such as Abbott, Roche, and Quidel, but differentiates itself through engineered protein binders that promise lower cost and greater stability.